Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO, Marc Voigt

Jessica Amir
August 26, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients’ tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results…

In this video Marc discusses:

  • (0:40) IMM’s progress: the year that was, and the year ahead
  • (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
  • (2:29) Its unique discovery in immunotherapy – which spells new opportunities
  • (4:02) Key catalysts that could drive share price growth
  • (6:00) Fund managers who bought into IMM recently – and how funds raised will be spent

Morning Bell 19 April

Sam Kanaan
April 19, 2024

Morning Bell 18 April

Grady Wulff
April 18, 2024

Morning Bell 17 April

Grady Wulff
April 17, 2024

Morning Bell 16 April

Sam Kanaan
April 16, 2024

Morning Bell 15 April

Grady Wulff
April 15, 2024

7 Minutes with 7 Executives

Bell Direct
April 12, 2024

Weekly Wrap 12 April

Grady Wulff
April 12, 2024

Morning Bell 12 April

Sam Kanaan
April 12, 2024

Morning Bell 11 April

Grady Wulff
April 11, 2024

Morning Bell 10 April

Grady Wulff
April 10, 2024